DocGo Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 9, 2026, covering the quarterly period ended September 30, 2026, reporting continued operating losses and a decline in total assets compared to year-end 2025.

Key Highlights

  • Nine-month net loss: DocGo reported a net loss of $52,984,178 for the nine months ended September 30, 2026, compared to a net loss of $54,026,555 for the same period in 2025.
  • Third-quarter revenue: Revenues, net for the three months ended September 30, 2026 were $73,431,205, up from $70,809,635 in the prior-year quarter, according to the filing.
  • Nine-month revenue decline: Revenues, net for the nine months ended September 30, 2026 totaled $222,406,408, compared to $247,260,312 for the same period in 2025.
  • Cash position: Cash and cash equivalents stood at $19,107,209 as of September 30, 2026, down from $51,018,657 as of December 31, 2025.
  • Total assets: Total assets were $173,900,854 as of September 30, 2026, compared to $217,103,012 as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $230,985,170 as of September 30, 2026, up from $183,801,795 as of December 31, 2025.
  • Shares outstanding: As of November 5, 2026, 98,992,347 shares of common stock were issued and outstanding, the filing disclosed.

DocGo's Financial Position and Operating Results Through September 30, 2026

According to the filing, DocGo Inc. (NASDAQ:DCGO) reported a loss from operations of $53,916,711 for the nine months ended September 30, 2026, compared to an operating loss of $73,453,991 for the nine months ended September 30, 2025. For the third quarter alone, the company reported a loss from operations of $17,283,397, compared to $41,976,309 in the prior-year quarter. The prior-year quarter included finite-lived intangible asset impairment of $8,020,343 and goodwill impairment of $8,718,398, which did not recur in the 2026 period, the filing showed.

Cost of revenues for the nine months ended September 30, 2026 was $151,654,671, compared to $172,867,109 for the same period in 2025. General and administrative expenses for the nine-month period were $89,479,434 versus $94,234,799 in the prior year. Legal and regulatory expenses were $14,803,686 for the nine months ended September 30, 2026, the filing stated. The company also reported insurance proceeds of $4,687,798 and a loss on change in fair value of contingent consideration of $3,560,000 for the nine-month period.

On the balance sheet, total stockholders' equity attributable to DocGo Inc. and Subsidiaries declined to $105,084,958 as of September 30, 2026, from $144,011,839 as of December 31, 2025. Total liabilities increased to $94,924,571 from $91,231,675 over the same period. The filing reported noncontrolling interests of $(26,108,675) as of September 30, 2026. Net loss per share attributable to DocGo stockholders was $(0.48) basic and diluted for the nine months ended September 30, 2026, based on weighted-average shares outstanding of 98,830,165.

What Was Disclosed

DocGo Inc. disclosed unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026, reflecting a nine-month net loss of $52,984,178, reduced cash balances, lower nine-month revenues, and an accumulated deficit of $230,985,170.